Press Release FeedGet the RSS feed
Menu

Business Wire

Immunis Chairman Dr. Hans Keirstead Nominated to Speak at SXSW 2027 on Restorative Approaches to Longevity Medicine

Business Wire

Nominated panel at SXSW's annual festival for health innovators, technologists, clinicians, and biotech pioneers explores how evidence-based science is shaping how we age and restore muscle function

IRVINE, Calif., August 20, 2026--Immunis, Inc., a clinical-stage biotechnology company developing off-the-shelf multi-active biologics for muscle health and healthy aging, today announced that its Chairman, Dr. Hans Keirstead, has been nominated as a panelist at SXSW 2027 in a conversation titled "Can We Get Better at Aging?: Hope, Hype, and Hard Science."

As medicine shifts from managing the effects of aging to designing therapeutics that help the body restore function, demand is growing for therapies that preserve muscle and metabolic health with age.

Chairman of Immunis, Dr. Keirstead, has been nominated to discuss the growing demand for multi-functional "cell-free, cell therapies" such as IMM01-STEM, with evidence supporting that it delivers the therapeutic benefits of stem cell-derived factors without the risk of administering live stem cells. Earlier this year, Immunis announced the most advanced clinical data on the class, showing improved muscle function and gait speed, a key vital indicator of health.

"The conversation around longevity has never been more important—or more crowded," says Dr. Keirstead. "For the first time, advances in AI, regenerative biology, and computational science are allowing us to ask questions that were unimaginable only a decade ago. People are inundated with promises about reversing aging, yet very few approaches are supported by rigorous clinical evidence. The future of healthy aging should be built on science that is measurable, reproducible, and focused on restoring quality of life, and responsible innovation that improves trust in the next generation of longevity medicine must be a priority."

SXSW, widely considered one of the largest and most influential convergence festivals of ideas, technology, culture and health, will take place in Austin, Texas from March 15-20, 2027. The nominated panel will explore topics in longevity medicine including rebuilding muscle as we age, promoting quality weight loss, and boosting metabolic function. Alongside Dr. Keirstead will be esteemed panelists Dr. Amelia Anderson, co-founder of Cyclarity who will discuss restoration in heart health, and Dr. Nathan Brady, co-founder of Fareon who specializes in restoration in brain health. To advance the conversation to the SXSW stage in March 2027, votes are being accepted until August 23 on SXSW.com by searching for the session or here by clicking the heart-shaped "vote" icon.

  1. Biotech & pharmaPfizer Inc.Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026Companies: PfizerInvestigational vaccine shows strong immune responses in infants equivalent to PREVNAR 20 ® on shared serotypes and for five new serotypes, potentially offering the broadest protection against invasive pneumococcal disease (IPD) for pediatric population in the U.S. NEW YORK, October 24, 2026--Pfizer I
  2. Biotech & pharmaIMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trialNovel combination demonstrated a median overall survival of nearly two years, the longest benefit ever reported in extensive stage disease in a Phase III trial Results reinforce IMFINZI as the backbone immunotherapy across stages of small cell lung cancer WILMINGTON, Del., October 24, 2026--Landmark re
  3. AutomotivePerioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancerMore than three quarters of patients were still alive two years after treatment with perioperative IMFINZI plus three cycles of EV given before surgery Data demonstrated statistically significant and clinically meaningful survival benefit and manageable safety profile WILMINGTON, Del., October 24, 2026 --
  4. ESMO 2026: NUBEQA® (darolutamide) Plus ADT and Radiation Therapy Reduces Risk of Metastasis or Death by 58% in Prostate Cancer Patients at High Risk of RecurrenceInterim analysis results from the Phase III DASL-HiCaP trial show a statistically significant 58% reduction in the risk of metastasis or death with NUBEQA® (darolutamide) versus placebo in addition to androgen deprivation therapy (ADT) and radiation therapy (hazard ratio [HR] 0.42; 95% CI: 0.27–0.66; p=0.0001) Four-year m
  5. FinanceSemtech CorporationSemtech Brings 5G Network Slicing, FIPS 140-3 to IACP 2026AirLink 5G Solutions Keep First Responders Connected During Peak Network Demand CAMARILLO, Calif., October 24, 2026--Semtech Corporation (Nasdaq: SMTC), a leading provider of high-performance semiconductors powering AI data center networking and intelligent, connected Internet of Things ("IoT") devices
  6. FinanceGenmab A/SGenmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal CancerCompanies: IncytePhase 1/2 study will evaluate petosemtamab plus INCB161734 and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer (mCRC) COPENHAGEN, Denmark & WILMINGTON, Del., October 24, 2026--Genmab A/S (Nasdaq: GMAB) and Incyte (Nasdaq: INCY) today announced a clinical tria